ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

lifitegrast

Also written as “Lifitegrast”, “Xiidra®” and “Lifitegrast/Perfluorohexyloctane Fixed Dose Combination”.

Its studies are mostly in Dry Eye Syndromes · Keratoconjunctivitis Sicca · Conjunctivitis, Allergic, led by 4 companies.

Drug pageLifitegrast: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Aug 17, 20119 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda60 open or runningphase 3since Aug 17, 2011Apr 15, 2009none ahead
Hoffmann-La Rocheits history only10 open or runningphase 4since Jun 16, 2025Jun 16, 2025none ahead
Qilu Pharmaceuticalits history only10 open or runningphase 1since Jun 18, 2025Jun 18, 2025none ahead
Research Insightits history only10 open or runningphase 4since Dec 9, 2020Dec 9, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Takeda only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 15, 2009First study: phase 2 study in Conjunctivitis, AllergicFirst studyNCT00882687 · 60 enrolled · United States
  2. Jun 20, 2009Phase 2 study in Dry Eye SyndromesNCT00926185 · 230 enrolled · United States
  3. Aug 17, 2011Phase 3 study in Keratoconjunctivitis SiccaNCT01421498 · 588 enrolled · United States
  4. Jul 5, 2012Phase 3 study in Dry Eye SyndromesNCT01636206 · 332 enrolled · United States
  5. Dec 3, 2012Phase 3 study in Dry Eye SyndromesNCT01743729 · 720 enrolled · United States
  6. Oct 30, 2014Phase 3 study in Dry Eye SyndromesNCT02284516 · 711 enrolled · United States

TargetBeta

“A tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 (LFA-1) antagonist, that can be used as an ophthalmic solution for the treatment of dry eye disease (DED; keratoconjunctivitis sicca; dry eye syndrome)”NCIt, by rule
“Integrin alpha-L/beta-2 (LFA-1) antagonist”ChEMBL 37, by rule

Studies

All 6 Takeda leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02284516Dry Eye Syndromes · United States3CompletedOct 5, 2015711
NCT01743729Dry Eye Syndromes · United States3CompletedOct 1, 2013720
NCT01636206Dry Eye Syndromes · United States3CompletedMar 3, 2014332
NCT01421498Keratoconjunctivitis Sicca · United States3CompletedApr 28, 2012588
NCT00926185Dry Eye Syndromes · United States2CompletedFeb 18, 2010230
NCT00882687Conjunctivitis, Allergic · United States2CompletedMay 10, 200960

How it is read

Names in the registry

  • “Lifitegrast”, 7 entries
  • “Xiidra®”, 1 entry
  • “Lifitegrast/Perfluorohexyloctane Fixed Dose Combination”, 1 entry
  • “Lifitegrast/perfluorohexyloctane (PFHO)”, 1 entry
  • “Xiidra”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.